All lobbying filings

FRESENIUS KABI USA LLC

FRESENIUS KABI USA LLC filed a Q2 report for FRESENIUS KABI USA LLC on July 20, 2026.

Lobbying for FRESENIUS KABI USA LLC

All filings by FRESENIUS KABI USA LLC · Everything FRESENIUS KABI USA LLC has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Expenses

$580,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Illinois

Official filing document

Government bodies contacted 11

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 6

Manufacturing

Domestic Manufacturing CMS Advance Notice of Proposed Rulemaking (ANPRM) on Domestic Manufacturing of Essential Medicines Use of industrial chemicals in medical devices Drug shortages and supply chain resilience

S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) PTAB Proposed Rule - Discretionary Denials and One and Done Ancillary Product Patent Reform

Taxation/Internal Revenue Code

Tax incentives for Onshoring Domestic Manufacturing of Essential Medicines

Trade (domestic/foreign)

S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act (BRTEA) S. 1414: Expedited Access to Biosimilars Act Section 301 Investigation re: Germany Issues Section 232 of the Trade Expansion Act: Patents as a Barrier to US Manufacturing of Biosimilars Inflation Reduction Act (IRA) redesigned Medicare Part D: Manufacturer Discount Program and Biosimilars CMS Advance Notice of Proposed Rulemaking (ANPRM) on Domestic Manufacturing of Essential Medicines PTAB Proposed Rule - Discretionary Denials and One and Done Federal Procurement Preferences for Domestic Medicines Drug Shortages and Supply Chain Resilience

Medicare/Medicaid

S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) CMS Advance Notice of Proposed Rulemaking (ANPRM) on Domestic Manufacturing of Essential Medicines Drug Shortages and Supply Chain Resilience PBM Transparency: Implementation of Consolidated Appropriations Act (CAA) Inflation Reduction Act (IRA) redesigned Medicare Part D: Manufacturer Discount Program and Biosimilars Net Elective Cost Policy: PBM Reform Through Bid Transparency

Health Issues

S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act (BRTEA) S. 1414: Expedited Access to Biosimilars Act PTAB Proposed Rule - Discretionary Denials and One and Done Domestic Production of Essential Medicines Federal Procurement Preferences for Domestic Medicines Ancillary Product Patent Reform CMS Advance Notice of Proposed Rulemaking (ANPRM) on Domestic Manufacturing of Essential Medicines Use of Industrial Chemicals in Medical Devices Drug Shortages and Supply Chain Resilience Employee Benefits Security Administration (EBSA) Proposed Rule Re: Broker/Consultant Transparency to Employer Plans Section 301 Investigation re: Germany Issues PBM Transparency: Implementation of Consolidated Appropriations Act (CAA) Section 232 of the Trade Expansion Act: Patents as a Barrier to US Manufacturing of Biosimilars Inflation Reduction Act (IRA) redesigned Medicare Part D: Manufacturer Discount Program and Biosimilars Net Elective Cost Policy: PBM Reform Through Bid Transparency

Bills named in this filing 6

S. 2658
Medication Affordability and Patent Integrity Act
S. 1954
Biosimilar Red Tape Elimination Act
H.R. 5526
Biosimilar Red Tape Elimination Act
S. 1414
Expedited Access to Biosimilars Act
S. 2276
ETHIC Act
H.R. 3269
ETHIC Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.